Reception of statins increases the risk of dementia twice

0
5
views

Scientists analyzed the condition of patients at regular reception of statins for eight years and came to the conclusion that they increase the risks of neurodegeneration more than twice. It is not yet clear how these results will affect the protocols of the treatment of people with a high level of cholesterol, which take these medicines every day.

Until now, clinical studies provided very controversial information on the role of statins in the development of dementia. Some argued that drugs are protected from neurodegeneration, while others, on the contrary, testified to the acceleration of its development. The team of scientists from the University of California in Los Angeles decided to put a point in this matter and assess the influence of statins on people in the long run.

Their work is due to the wide demand for statins among the elderly worldwide, which are prescribed drugs to control cholesterol. For example, only in the US, almost 50% of people after 75 years accept them constantly to reduce the risks of stroke and infarction.

The team concentrated on hydrophilic statins acting on the liver and lipophilic statins distributed over all tissues of the body. The study was attended by 303 patients who either demonstrated the light signs of cognitive violations, or did not have signs of dementia. All volunteers were divided into subgroups by the types of statins taken, cholesterol and cognitive status. Observation lasted for eight years.

It is noteworthy that at the initial stage of the experiment, the level of cholesterol in the blood serum in this person in this subgroup was low or moderate.

The results were obtained when compared with the reception of hydrophilic statins, as well as among people with a higher initial level of cholesterol, which did not take medication.

Risk assessment was carried out using PET scanning brain, which showed the level of metabolism in the rear cortex. It is known that people with dementia have this area of the brain affects the earliest stages.

It is not yet clear how these results will affect the existing treatment protocols.

«Currently, they can be used to inform patients regarding the decision on the admission of statins and the choice of the most optimal drug,» the authors concluded.

Over the past year, it is clear that COVID-19 can be considered a new risk factor. Recently another group of researchers from the USA


We tell about the most interesting news and technologies — from the upcoming total automation to alternative energy, from artificial intelligence to the future medicine.

Hayk +